Counselling Code : VBIT

VIGNANA BHARATHI Institute of Technology

(A UGC Autonomous Institution, Approved by AICTE, Accredited by NBA & NAAC-A Grade, Affiliated to JNTUH)

A MAJOR PROJECT REPORT

ON

DATA DRIVEN PREDICTION OF DRUG INTERACTIONS

Submitted in partial fulfillment of the requirement
for the award of the degree of

BACHELOR OF TECHNOLOGY
IN

COMPUTER SCIENCE AND ENGINEERING
(Data Science)

BY

K.Samvedya	**21P61A6791**
R.Jatin	**21P61A6777**
G.Murali	**21P61A6769**

Under the esteemed guidance of
Ch.Sathyanarayana
Assistant Professor
Dept. of CSD

VIGNANA BHARATHI INSTITUTE OF TECHNOLOGY

(A UGC Autonomous Institution, Approved by AICTE, Affiliated to JNTUH,

Accredited by NBA & NAAC) Aushapur (V), Ghatkesar (M), Medchal(dist.)

April – 2025

Counselling Code : VBIT

VIGNANA BHARATHI Institute of Technology ®

(A UGC Autonomous Institution, Approved by AICTE, Accredited by NBA & NAAC-A Grade, Affiliated to JNTUH)

Aushapur (V), Ghatkesar (M), Hyderabad, Medchal – Dist, Telangana – 501 301.

DEPARTMENT OF
COMPUTER SCIENCE & ENGINEERING
(Data Science)

CERTIFICATE

This is to certify that the major project titled ***"Data Driven Prediction Of Drug Interactions"*** *submitted by* ***K.Samvedya(21P61A6791),R.Jatin(21P61A6777),G.Murali(21P61A6769)in***. *B.Tech. IV-II semester Computer Science & Engineering (Data Science) is a record of the bonafide work carried out by them.*

The results embodied in this report have not been submitted to any other University for the award of any degree

INTERNAL GUIDE
Ch. Sathyanarayana
(Assistant Professor)

PROJECT CO-ORDINATOR
Dr. P. Punitha
(Associate Professor)

HEAD OF THE DEPARTMENT
Dr. Y. Raju
(Associate Professor)

EXTERNAL EXAMINER

DECLARATION

We,**K.Samvedya,R.Jatin,G.Murali** bearing hall ticket number **21P61A6791, 21P61A6777,21P61A6769** here by declare that the major project report entitled "**Data Driven Prediction Of Drug Interactions**" under the guidance of **Ch. Sathyanarayana**, Assistant Professor, Department of Computer Science and Engineering (Data Science), Vignana Bharathi Institute of Technology, Hyderabad, have submitted to Jawaharlal Nehru Technological University Hyderabad, Kukatpally, in partial fulfillment of the requirements for the award of the degree of Bachelor of Technology in Computer Science and Engineering (Data Science).

This is a record of bonafide work carried out by us and the results embodied in this project have not been reproduced or copied from any source. The results embodied in this project report have not been submitted to any other university or institute for the award of any other degree or diploma.

K. Samvedya:21P61A6791

R. Jatin: 21P61A6777

G. Murali :21P61A6769

ACKNOWLEDGEMENT

We are extremely thankful to our beloved Chairman, **Dr. N. Goutham Rao** and Secretary**, Dr. G. Manohar Reddy** who took keen interest to provide us the infrastructural facilities for carrying out the project work, Self-confidence, hard work, commitment and planning are essential to carry out any task. Possessing these qualities is sheer waste, if an opportunity does not exist. So, we whole- heartedly thank **Dr. P. V. S. Srinivas,** Principal, and **Dr. Y. Raju**, Head of the Department, Computer Science and Engineering (Data Science) for their encouragement and support and guidance in carrying out the project.

We would like to express our indebtedness to the project coordinator, **Dr. P. Punitha**, Associate Professor, Department of CSE (Data Science) for her valuable guidance during the course of project work.

We thank our Project Guide, **Ch.Sathyanarayana,** Assistant Professor, for providing us with an excellent project and guiding us in completing our major project successfully.

We would like to express our sincere thanks to all the staff of Computer Science and Engineering, VBIT, for their kind cooperation and timely help during the course of our project. Finally, we would like to thank our parents and friends who have always stood by us whenever we were in need of them.

ABSTRACT

Drug-Drug Interactions (DDIs) pose significant challenges in clinical practice, affecting treatment efficacy and patient safety. This project presents a deep learning-based approach for the accurate and efficient prediction of DDIs by integrating heterogeneous drug-related data, including chemical properties, biological targets, and phenotypic effects. Leveraging a model built with Keras and TensorFlow, trained on drug feature matrices and similarity scores, the system identifies potential interactions with high accuracy. A Streamlit-based web application enables real-time interaction analysis, supporting healthcare professionals and researchers in making informed decisions. This data-driven method addresses the limitations of traditional experimental approaches by providing a scalable, cost-effective solution for predicting and managing drug interactions, thereby contributing to safer and more effective therapeutic strategies

Keywords:

Drug-Drug Interactions (DDIs),Drug Similarity Matrices, Deep Learning,Streamlit Web Application

DEPARTMENT OF COMPUTER SCIENCE AND ENGINEERING (DATA SCIENCE)

VISION:

To be recognized as a Centre of Excellence in Data Science to meet the ever growing needs of Industry and Society.

MISSION:

- To empower students with innovative and cognitive skills to gain expertise in the field of Data science.
- To inculcate the seeds of knowledge by providing industry conducive environment to enable students excel in the field of Data Science.
- To provide an appropriate ambience to nurture the young Data Science professionals.

PROGRAM EDUCATIONAL OBJECTIVES (PEOs)

PEO 1: Domain Knowledge: Impart strong foundation in basic sciences, Mathematics, Engineering and emerging areas by advanced tools and Technologies.

PEO 2: Professional Employment: Develop Professional skills that prepare them for immediate employment in industry, government, entrepreneurship and R&D.

PEO 3: Higher Degrees: Motivation to pursue higher studies and acquire masters and research.

PEO 4: Engineering Citizenship: Communicate and work effectively, engage in team work, achieve professional advancement, exhibit leadership skills, and ethical attitude with a sense of social responsibility.

PEO 5: Lifelong Learning: Lead edge of the industrial engineering discipline and respond to challenges of an ever-changing environment with the most current knowledge and technology.

PROGRAM OUTCOMES (POs)

Engineering graduates will be able to:

1. **Engineering Knowledge**: Apply the knowledge of mathematics, science, engineering fundamentals, and an engineering specialization to the solution of complex engineering problems.
2. **Problem Analysis**: Identify, formulate, review research literature, and analyse complex engineering problems reaching substantiated conclusions using first principles of mathematics, natural sciences, and engineering sciences.
3. **Design/development of solutions**: Design solutions for complex engineering problems and design system components or processes that meet the specified needs with appropriate consideration for the public health and safety, and the cultural, and environmental considerations.
4. **Conduct investigations of complex problems**: Use research-based knowledge and research methods including design of experiments, analysis and interpretation of data, and synthesis of the information to provide valid conclusions.
5. **Modern tool usage**: Create, select, and apply appropriate techniques, resources, and modern engineering and IT tools including prediction and modelling to complex engineering activities with an understanding of the limitations.
6. **The engineer and society**: Apply reasoning informed by contextual knowledge to assess societal, health, safety, legal and cultural issues, and the consequent responsibilities relevant to professional engineering practice.
7. **Environment and sustainability**: Understand the impact of professional engineering solutions in societal and environmental contexts, and demonstrate the knowledge of, and need for sustainable development.
8. **Ethics**: Apply ethical principles and commit to professional ethics and responsibilities and norms of engineering practice.
9. **Individual and team work:** Function effectively as an individual, and as a member or leader in diverse teams, and in multidisciplinary settings.
10. **Communication**: Communicate effectively on complex engineering activities with the engineering community and with society at large, such as being able to comprehend and write effective reports and design documentation, make effective Presentations, and give and receive clear instructions.

11. **Project management and finance**: Demonstrate knowledge and understanding of the engineering and management principles and apply these to one's own work, as a member and leader in a team, to manage projects and in multidisciplinary Environments.

12. **Life-long learning**: Recognize the need for and have the preparation and ability to engage in independent and life-long learning in the broadest context of technological change.

PROGRAM SPECIFIC OUTCOMES (PSOs)

PSO1: Understand fundamental concepts in statistics, mathematics and computer Science to gain an understanding and working knowledge of various tools for analysis.

PSO2: Represent the knowledge, predicate logic and then transform the real life information into visually appealing data using suitable tools.

PSO3: Get Expertise in different aspects and appropriate models of Data Science and use large data sets to cater to the growing demand for data scientists and engineers in industry.

Course Outcomes (COs)

CO1 - Identify the problem by applying acquired knowledge from survey of technical publications.

CO2 - Analyze and categorize identified problem to formulate and fine the best solution after considering risks.

CO3 - Choose efficient tools for designing project.

CO4 - Build the project through effective team work by using recent technologies.

CO5 - Elaborate and test the completed task and compile the project report.

Correlation Levels

Substantial/ High	3
Moderate/ Medium	2

CO – PSO Correlation Matrix

COs	PSOs		
	PSO1	PSO2	PSO3
CO1	2	2	3
CO2	3	2	2
CO3	2	3	
CO4	2	2	3
CO5		2	2
CO	1.8	2.2	2

CO – PO Correlation Matrix

COs	POs											
	PO1	PO2	PO3	PO4	PO5	PO6	PO7	PO8	PO9	PO10	PO11	PO12
CO1	3	2	2	2	2	2	2	3	2	2	2	3
CO2	2	3	3	3	2	2	2	3	3	3	3	2
CO3	3	2	2	2	3	3	3	3	2	2	2	2
CO4	2	3	3	2	2	2	2	3	3	3	3	2
CO5	2	2	2	2	3	3	3	3	2	2	2	2
	2.4	2.4	2.4	2.2	2.4	2.4	2.4	3	2.4	2.4	2.4	2.2

Project Outcomes (PROs)

1. Accurate and Scalable Prediction of Drug-Drug Interactions:

The deep learning model developed in this project effectively predicts potential drug-drug interactions by learning from complex and high-dimensional drug-related data. By integrating chemical structures, biological targets, and phenotypic effects, the model achieves high predictive accuracy, making it a reliable tool for large-scale DDI screening.

2. Integration of Heterogeneous Drug Data Sources:

A major outcome of this project is the successful fusion of diverse drug-related datasets into a unified analytical pipeline. By combining chemical properties, target proteins, and observed drug effects, the system provides a more holistic understanding of how drugs interact, significantly improving the reliability of interaction predictions.

3. Deployment of an Interactive Web Application for Clinical Use:

A user-friendly Stream lit-based web application was developed to make the model's capabilities accessible in real time. This application allows clinicians, pharmacists, and researchers to input drug data and receive immediate interaction insights, enhancing decision-making in both clinical and research settings.

4. Support for Safer and More Effective Therapeutic Decisions:

By identifying harmful or unexpected drug interactions before prescription, this tool aids healthcare professionals in optimizing treatment plans. This contributes directly to patient safety, reducing the risk of adverse drug reactions and improving overall treatment outcomes.

5. Cost-Effective and Time-Efficient Alternative to Traditional Methods:

Unlike traditional experimental approaches that are time-consuming and resource-intensive, this AI-driven system offers a scalable and economical method for DDI prediction. It enables rapid analysis across large drug datasets, making it suitable for both clinical applications and pharmaceutical research.

PRO – PSO Correlation Matrix

PROs	PSOs		
	PSO1	PSO2	PSO3
PRO1	3	2	3
PRO2	2	3	2
PRO3	2	2	3
PRO4	2	2	2
PRO5	2	2	3
	2.2	2.2	2.6

PRO – PO Correlation Matrix

PROs	POs											
	PO1	PO2	PO3	PO4	PO5	PO6	PO7	PO8	PO9	PO10	PO11	PO12
PRO1	2	2	3	2	3	3	3	3	2	3	2	2
PRO2	3	3	3	3	3	2	2	3	2	3	3	3
PRO3	2	2	2	2	2	2	2	3	2	2	2	3
PRO4	2	2	3	2	2	2	2	3	3	3	2	2
PRO5	3	2	2	3	3	3	3	3	2	2	2	2
	2.4	2.2	2.6	2.4	2.6	2.6	2.6	3	2.2	2.6	2.2	2.4

TABLE OF CONTENTS

List of Figures

CHAPTER-1

1. INTRODUCTION

1.1 Introduction:

Drug-Drug Interactions (DDIs) play a crucial role in ensuring patient safety and optimizing treatment outcomes. Understanding how different drugs interact is essential, as positive interactions can enhance therapeutic benefits, while negative interactions may lead to severe complications, including adverse drug reactions and potentially fatal outcomes. The accurate identification and prediction of DDIs are paramount in clinical settings to minimize risks and improve healthcare interventions.

As the number of available pharmaceuticals continues to grow, healthcare professionals and researchers face an increasing challenge in managing potential drug interactions. The consequences of undetected negative DDIs can be severe, including prolonged hospitalizations, life-threatening side effects, and increased healthcare costs. In worst-case scenarios, adverse interactions may result in permanent health complications or fatalities. Consequently, there is a pressing need for improved methods to identify and mitigate these risks efficiently.

Traditional experimental methods for identifying DDIs, such as in vitro (laboratory-based) and in vivo (animal or human-based) studies, provide valuable insights but have inherent limitations. These methods are not only time-consuming and costly but also lack scalability, making them impractical for evaluating the vast number of potential drug combinations that exist today. Clinical trials, while essential for drug approval and safety assessment, often cannot explore every possible interaction due to ethical, financial, and logistical constraints.

In light of these challenges, computational approaches have emerged as a powerful alternative for predicting DDIs. By leveraging data-driven techniques such as artificial intelligence (AI) and machine learning (ML), researchers can analyze large-scale datasets containing chemical, biological, and clinical drug information. These computational models can efficiently detect patterns and predict potential interactions with greater accuracy and speed compared to traditional methods.

1.2 Motivation:

With the increasing complexity of medical treatments, patients are often prescribed multiple drugs simultaneously, increasing the risk of unintended and potentially dangerous drug interactions. The consequences of DDIs can range from mild side effects to severe health complications and even fatalities. In many cases, adverse interactions go unnoticed until clinical symptoms arise, leading to increased healthcare costs and prolonged hospital stays.

Moreover, pharmaceutical companies and healthcare providers face challenges in identifying and managing DDIs using traditional experimental techniques. These methods are not only resource-intensive but also incapable of keeping pace with the rapid emergence of new drugs and their potential interactions. Computational approaches, particularly those leveraging artificial intelligence and machine learning, offer an innovative solution to this problem by enabling efficient, large-scale DDI prediction.

1.3 Problem Statement:

The primary problem addressed in this research effort is the lack of an efficient, scalable, and accurate method for identifying DDIs. Current experimental techniques are inadequate in evaluating the vast number of potential drug interactions, leading to significant gaps in knowledge. Unidentified interactions pose a major risk to patient safety and can hinder effective drug development.

This initiative aims to tackle these challenges by utilizing computational models to predict DDIs based on chemical, biological, and phenotypic drug properties. The goal is to develop a robust system capable of analyzing extensive datasets to identify possible interactions with greater accuracy, speed, and cost-efficiency than traditional methods.

1.4 Aim of the Project:

Prevent adverse effects

One of the primary reasons for studying DDIs is to prevent severe adverse effects that can arise when multiple drugs interact negatively. Unforeseen drug interactions can lead to severe complications, increased hospitalization rates, drug withdrawals from the market, and even fatalities. Identifying these interactions early can help medical professionals make informed decisions to mitigate risks and improve patient safety.

Improve Multi-Drug Therapies

Many patients, especially those suffering from chronic and complex diseases such as cancer, cardiovascular disorders, and diabetes, require multi-drug therapies. These therapies involve administering multiple medications simultaneously, increasing the likelihood of drug interactions. Predicting and managing DDIs effectively enhances the safety and efficacy of these treatments, ensuring that patients receive optimal therapeutic benefits while minimizing harmful side effects.

Reduce Development Costs

Developing new drugs is an expensive and time-intensive process, often taking years before a medication reaches the market. Traditional experimental methods for DDI detection, such as laboratory testing and clinical trials, add to these costs. By leveraging computational models and machine learning techniques, pharmaceutical companies can predict potential DDIs more efficiently, significantly reducing the time and financial resources required for drug development and regulatory approval.

Ensure Patient Safety

Patient safety is the cornerstone of modern healthcare, and understanding DDIs plays a vital role inthis regard. By identifying potential harmful drug interactions before prescribing medications, healthcare providers can design safer drug regimens. This proactive approach helps in preventing complications that could arise from unforeseen interactions, ensuring better therapeutic outcomes for patients.

Address Experimental Limitations

While in vitro and in vivo methods remain essential in pharmacological research, they come with inherent limitations. These traditional techniques are often labor-intensive, costly, and not scalable for evaluating the extensive range of possible drug combinations. Additionally, they may not always capture complex biological interactions that occur in real-world clinical settings. Computational approaches provide an efficient alternative by enabling large-scale analysis of drug interactions with greater precision and reliability.

Support Synergistic Drug Combinations

In addition to identifying harmful interactions, the study will also explore beneficial drug interactions that can enhance treatment efficacy. By optimizing multi-drug therapies, this approach aims to contribute to personalized medicine, where drug combinations are tailored to maximize patient outcomes.

Enable Efficient Predictions with Computational Approaches

The use of artificial intelligence and machine learning allows for rapid and accurate DDI predictions. By leveraging data-driven models, the proposed framework seeks to provide a scalable solution that can quickly analyze vast datasets, predict interactions, and provide valuable insights to researchers and healthcare professionals.

CHAPTER-2

2. LITERATURE REVIEW

2.1 Extraction of Drug-Drug Interactions from Biomedical Literature: A Case Study Approach

Smith,J.

This study explores the use of natural language processing (NLP) techniques to extract drug-drug interaction (DDI) information from biomedical literature. It analyzes various text-mining tools that automatically extract interactions from scientific papers and electronic health records. The study also evaluates different datasets used for training machine learning models in DDI detection. The research highlights the importance of linguistic patterns in identifying and categorizing interactions. The findings emphasize the potential of AI-driven automation in improving pharmacovigilance.

2.2 Machine Learning Techniques for Drug-Drug Interaction Prediction

Johnson,L.

This paper provides a detailed review of various machine learning models applied to predict DDIs. It discusses supervised and unsupervised learning techniques, highlighting their performance in DDI identification. The study evaluates traditional models like decision trees, support vector machines, and neural networks. It emphasizes the importance of feature selection and model interpretability. The authors also discuss how different datasets and features influence predictive accuracy

2.3 Natural Language Processing for Extracting Drug-Drug Interactions from Text

Davis,M.

This research explores the use of NLP in identifying DDIs from biomedical literature, clinical and social media content. Various NLP techniques, such as named entity recognition (NER) and deep learning models like transformers, are analyzed. The study highlights the importance of syntactic and semantic analysis in extracting meaningful DDI relationships. It also discusses the challenges posed by unstructured text and polysemous drug names. The research further explores the potential for real-time DDI detection in healthcare applications.

2.4 Multi-Modal Data Integration for Drug-Drug Interaction Prediction

Anderson,P.

The study focuses on combining multiple data sources, such as genomic, chemical, and clinical data, to improve DDI prediction accuracy. It emphasizes the need for integrated frameworks that leverage different data types for a holistic understanding.

The research discusses various computational methods, including deep learning and knowledge graphs. Results indicate that multi-modal data integration enhances the predictive power of DDI models. The study also highlights the potential of data fusion techniques to improve model robustness.

2.5 Deep Learning-Based Approaches for DDI Prediction

Dawson,H.

This paper examines deep learning models like convolutional neural networks (CNNs) and recurrent neural networks (RNNs) for DDI prediction. It evaluates their effectiveness in analyzing complex relationships between drugs at the molecular and clinical levels. The study discusses how deep learning can automatically extract meaningful features from raw data. Additionally, it highlights the challenges of interpretability and data requirements in deep learning models. The research also explores transfer learning as a method to improve model generalization.

2.6 Adverse Drug Reactions and Drug-Drug Interaction Prediction Using Supervised Learning

Clark,P.

This study investigates how supervised machine learning models can predict DDIs using adverse drug reaction datasets. It highlights the role of feature engineering in improving predictive accuracy. The authors compare different classification models, including decision trees, random forests, and deep neural networks. The study emphasizes the importance of high-quality labeled data for training machine learning models. It concludes that deep learning methods outperform traditional machine learning approaches in DDI prediction.

2.7 Existing System:

Experimental Methods:

Traditional experimental methods have been the cornerstone of drug-drug interaction (DDI) identification for decades. These methods primarily rely on laboratory-based and clinical trial methodologies, including in vitro and in vivo studies. In vitro assays involve testing drug interactions on cell cultures in a controlled laboratory environment, which helps in understanding how drugs interact at the molecular and biochemical levels. These assays provide valuable information regarding enzyme inhibition, receptor binding affinity, and metabolic pathways of drugs. On the other hand, in vivo studies involve testing drug interactions in living organisms, including animal models and human clinical trials. These studies assess the physiological and systemic impacts of drug combinations, providing insight into real-world drug behavior. However, these methods are highly resource-intensive, time-consuming, and impractical for large-scale DDI analysis.

Pharmacokinetic and Molecular Models

Computational models have been increasingly utilized to predict potential DDIs based on pharmacokinetics and molecular similarities. The Physiologically Based Pharmacokinetic (PBPK) Model is a widely used simulation-based approach that predicts how drugs interact based on their metabolism properties. For example, studies have demonstrated that crizotinib interacts with ketoconazole or rifampin by altering metabolic enzyme activity, leading to modified drug efficacy. Another approach, Molecular Similarity Analysis, relies on comparing drug structures in two-dimensional (2D) and three-dimensional (3D) spaces. Researchers such as Vilar et al. have developed computational frameworks that analyze molecular structures, target similarities, and side effects to identify large-scale DDIs. These models offer a more scalable alternative to traditional experimental methods; however, they are still limited by incomplete datasets and inherent challenges in molecular feature extraction.

Bayesian and Probabilistic Models

Bayesian and probabilistic models have been explored for DDI prediction due to their ability to incorporate uncertainty and prior knowledge in drug interaction analysis. Bayesian Networks, such as the model developed by Li et al., leverage probabilistic reasoning to discover drug combination efficacy based on molecular and phenotypic similarities.

These networks represent drug interactions as probabilistic relationships, making them suitable for modeling complex interactions. Another probabilistic approach, Probabilistic

Soft Logic (PSL), integrates multiple drug similarity networks to predict novel DDIs. PSL enables flexible and scalable interaction prediction by leveraging diverse similarity measures. Despite their advantages, Bayesian and probabilistic models require extensive domain knowledge for accurate probability estimation, and their performance is highly dependent on the availability and completeness of data sources.

Limitations of Current Approaches

Despite advancements in DDI prediction, existing methods face several limitations that hinder their effectiveness in large-scale drug interaction analysis. High Cost and Time Consumption: Traditional experimental methods, such as clinical trials and in vitro assays, are expensive and time-consuming, making them impractical for assessing a vast number of drug combinations.Limited Scalability: Current models struggle to analyze large datasets due to computational constraints and data integration challenges. Limited Generalizability: Many existing DDI prediction models are trained on specific datasets and fail to generalize well to new drug interactions. High Computational Complexity: Advanced deep learning and probabilistic models require significant computational resources, making them challenging to implement in real-time clinical applications. Data Integration Challenges: Fragmented and heterogeneous data sources limit the ability to capture the full spectrum of drug properties, leading to gaps in DDI prediction accuracy.

2.8 Proposed System:

To address the challenges in existing Drug-Drug Interaction (DDI) prediction methods, the proposes system introduces an advanced deep learning-based framework that integrates neural networks with pharmacological and biomedical data for improved accuracy and efficiency. The system leverages feature-rich datasets, including drug chemical properties, similarity matrices, and interaction patterns, to enhance predictive capabilities and minimize false positives in DDI detection.

Objective

The primary goal of this initiative is to develop a robust AI-driven model capable of predicting potential DDIs with high accuracy, ensuring safer medication practices and optimizing drug administration.

The framework is designed to achieve the following:

1. Prevent Adverse Drug Reactions: By identifying harmful drug interactions in advance, the system aims to reduce the risk of severe side effects, hospitalizations, and life-threatening complications, thereby improving patient safety.
2. Enhance Multi-Drug Therapies: The proposed model facilitates safer prescription of multiple drugs in complex treatment regimens for chronic diseases such as cardiovascular conditions, diabetes, and cancer. This ensures the effectiveness and safety of multi-drug therapies.
3. Reduce Drug Development Costs: Traditional drug interaction testing is time-consuming and expensive. By integrating deep learning techniques, the framework minimizes the reliance on costly in vitro and in vivo testing, accelerating the drug discovery and approval process.
4. Optimize Treatment Strategies: The system not only detects potential negative interactions but also supports the identification of synergistic drug combinations, which is crucial in developing targeted therapies for diseases like cancer and neurodegenerative disorders
5. Scalable and Efficient Predictions: The deep learning model efficiently processes large-scale datasets, extracting meaningful insights from drug feature matrices and similarity data. This enables faster and more accurate predictions compared to conventional computational approaches.
6. Real-Time Prediction and Decision Support: The system is deployed as an interactive Streamlit-based application, allowing healthcare professionals and researchers to input drug names and receive real-time predictions on possible interactions, probability scores, associated side effects, and target site information.
7. AI-Powered Analysis for Improved Accuracy: Unlike traditional models that rely on predefined rules, this framework employs a deep learning architecture trained on high-dimensional drug features, ensuring adaptability and precision in DDI prediction. The model processes fused similarity matrices and drug embeddings to enhance predictive performance.

CHAPTER-3

3. FEASIBILITY STUDY

3.1 FEASIBILITY STUDY

A feasibility study is a high-level capsule version of the entire system analysis and Design process. The study begins by classifying the problem definition. Feasibility is to determine if it's worth doing. Once an acceptance problem definition has been generated, the analyst develops a logical model of the system. A search for alternatives is analyzed carefully.

Three key considerations involved in the feasibility analysis are

- Technical Feasibility
- Operational Feasibility
- Economical Feasibility

3.1.1 Technical Feasibility

To determine whether the proposed system is technically feasible, a number of issues have to be considered while doing technical analysis. Understand the different technologies involved in the proposed system. Find out whether the organization currently possesses the required technologies.

3.1.2 Operational Feasibility

Operationally, the system is designed with user-friendliness in mind. The Streamlit-based interface ensures that healthcare professionals, pharmacists, or researchers can easily interact with the application. Minimal training is required to use the tool, and its visual feedback on drug interactions, side effects, and target sites enhances understanding. The system is likely to be accepted by users as it streamlines drug interaction checks, supports informed decision-making, and can help prevent adverse reactions.

3.1.3 Economical Feasibility

To decide whether a project is economically feasible, we have to consider various factors

3.1.2.1 Cost benefit analysis

3.1.2.2 Long-term returns

3.1.2.3 Maintenance costs

CHAPTER-4

4.1 Hardware Requirement Specification:

Hardware Requirements

1. Processor

- Intel Pentium IV or higher
- A multi-core processor is recommended for faster computations.

2. RAM

- Minimum: 4 GB
- Recommended: 8 GB or more (for handling large datasets and model training).

3. Hard Disk

- Minimum: 20 GB of free space

4. Keyboard & Mouse

- Standard Windows Keyboard
- Two or Three Button Mouse

5. Monitor

- SVGA or higher resolution display
- A larger screen size is recommended for ease of working with data visualizations.

4.2 Software Requirements:

The system utilizes multiple software components for data processing, machine learning, and web application development.

1. Windows 10/11 (Operating System)

The system is developed and tested on Windows 11 a stable and widely compatible operating system that supports a variety of software development tools. It provides a secure and efficient environment for running Python scripts, database management, and web applications. Though newer versions of Windows are available, Windows 7 remains a preferred choice for many legacy systems due to its reliability.

2. Python (Programming Language)

The core of the system is implemented in Python 3.x, a widely used language for machine learning and web applications.
Key libraries include:

- NumPy & Pandas – Used for data manipulation and numerical operations.
- Keras & TensorFlow – Provides deep learning model implementation and training.
- Streamlit – Used for building the interactive web application.
- Matplotlib & Seaborn – Enables data visualization and model performance analysis.

3. Deep Learning Framework

- The system utilizes Keras, a high-level deep learning API, built on TensorFlow, which is widely used for developing and training deep neural networks.
- The trained interaction model is loaded using Keras' load_model() function, allowing seamless integration of pre-trained weights and architecture.
- TensorFlow supports GPU acceleration, enabling faster computation for real-time predictions.

- The deep learning model takes drug feature matrices and similarity matrices as input, processing them through fully connected layers to generate interaction probability scores.

4. Data Management

- CSV Files: Drug-related metadata, such as drug names, side effects, and target site information, is stored in structured CSV files .
- Pandas is used for loading and processing these files efficiently.
- NumPy Arrays: Large-scale numerical data, including drug feature vectors and similarity matrices, is stored in NumPy (.npy) files for fast retrieval and processing.

5. Web Application Framework

- The front-end user interface is built using Streamlit, a Python-based web framework designed for interactive data applications.
- Streamlit allows real-time data interaction without the need for complex front-end coding.
- Provides an easy-to-use UI for drug selection, prediction, and result visualization.

6. Machine Learning Model

- The system uses a deep learning model trained on drug-drug interaction data.
- The model is loaded from a pretrained Keras file (final_model.keras), which contains the saved architecture and learned weights.
- The system uses a **deep learning model** trained on drug similarity and feature matrices.
- The model predicts: Drug interaction probability,Side effects,Target site information.
- The model is loaded from an HDF5/Keras file (final_model.keras).

7. Caching & Performance Optimization

- Streamlit Caching: Improves performance by caching frequently used data and resources, preventing unnecessary recomputation.
- Caches drug metadata and similarity matrices to avoid redundant file loading.
- Caches the trained Keras model (final_model.keras), ensuring it is loaded only once per session

CHAPTER-5

5.METHODOLOGY

5.1 Research Approach

The design approach for the DDI Prediction System focuses on developing a scalable, AI-powered, and user-friendly framework that leverages deep learning to predict drug-drug interactions (DDIs) with high precision. The approach is structured around key principles such as data-driven decision-making, computational efficiency, accessibility, and continuous learning.

1. Data-Driven and Scalable Architecture

The system is designed to process large-scale pharmacological datasets efficiently while integrating various drug-related features such as chemical properties, biological effects, and similarity matrices. It employs a structured data pipeline to handle:

- Preprocessed drug feature embeddings stored in NumPy arrays for fast access.
- Side effect and target site information retrieved from structured CSV datasets.
- Deep learning models deployed using Keras, ensuring high-speed inference.
- The backend efficiently manages this data using optimized data handling techniques, including caching and preloading to improve model execution speed.

2. AI-Driven Prediction Mechanism

At the core of the framework is a supervised deep learning model, trained on diverse drug datasets. The model utilizes drug feature embeddings and similarity matrices to predict potential interactions. The system's AI pipeline includes:

- Feature Fusion: Combining chemical, biological, and similarity-based features for comprehensive analysis.
- Neural Network-Based Predictions: Using a Keras-based deep learning model for high-accuracy DDI classification.
- Probability Estimation: The model outputs interaction probabilities, helping users understand the likelihood of adverse interactions.
- The AI-driven mechanism allows for rapid, reliable, and scalable predictions compared to traditional rule-based or statistical approaches.

3. User-Centric and Accessible Web Interface

To ensure ease of use, the DDI prediction system is integrated with a Streamlit-based UI, providing an interactive experience with:

- Dropdown selection for drug inputs, allowing users to enter and compare drugs.
- Real-time prediction results, displaying interaction probabilities and potential side effects.
- Detailed drug insights, including associated risks and target sites.
- The lightweight Streamlit UI ensures accessibility across various devices, enabling researchers and healthcare professionals to seamlessly analyze drug interactions.

4. Continuous Model Improvement and Validation

To enhance long-term system reliability, the framework integrates continuous improvement mechanisms, including:

Cross-validation techniques to maintain model accuracy and prevent overfitting.

Real-time feedback collection from healthcare professionals for model refinement.

Regular model updates incorporating newly available drug interaction data.

By adopting a feedback-driven approach, the system ensures its predictions remain accurate, up-to-date, and aligned with real-world pharmacological research.

This design approach makes the DDI prediction system a powerful, AI-driven tool for improving drug safety, reducing adverse effects, and enhancing decision-making in pharmaceutical and clinical settings.

5.2. UML Diagrams:

5.2.1. Use Case Diagram:



Figure 5.2.1 Use Case Diagram

5.2.2. Class Diagram:



Figure 5.2.2 Class diagram

5.2.3 Activity Diagram:



Figure 5.2.3 Activity Diagram

5.2.4 Sequence Diagram:



Figure 5.2.4 Sequence Diagram

CHAPTER-6

6.IMPLEMENTATION

6.1 Development Overview

The development environment consists of tools and platforms used for building, testing, and deploying the system. It includes:

- Programming Languages: e.g., Python, JavaScript, Java, etc.
- Frameworks/Libraries: e.g., React, Node.js, Django, TensorFlow, etc.
- Code Editor/IDE: e.g., Visual Studio Code, IntelliJ IDEA, PyCharm
- Version Control System: Git with GitHub/GitLab/Bitbucket for repository management
- Package Managers: npm, pip, Maven (depending on stack)
- Databases: e.g., PostgreSQL, MongoDB, MySQL

6.2 System Setup and Configuration

This phase involves preparing the environment to run and support the application or system.

- Installation of Required Tools: Set up programming language runtimes, IDEs, and dependencies.
- Environment Configuration:
- .env files for environment variables
- Database setup and credentials
- API keys and access tokens
- Database Configuration:
- Local development and testing databases created
- Database schema migration and seed data setup
- Server Setup:
- Local server with Node.js/Django/Flask/etc.
- Configuration files such as package.json, docker-compose.yml, or settings.py
- Build and Run:
- Command scripts or Makefiles for starting services
- Docker containers (if used) built and networked

6.3 Challenges During Implementation

- Dependency Conflicts: Compatibility issues between different libraries or frameworks
- Environment Discrepancies: Differences between development and production environments (solved by using Docker/VMs)
- Database Migrations: Handling schema changes during development without losing data
- Debugging and Testing: Identifying edge cases and ensuring code stability
- Performance Bottlenecks: Especially in backend services or API integration
- Security Concerns: Managing authentication, authorization, and secure data storage
- Learning Curve: New tools, languages, or frameworks introduced to the team

6.4 Sample Code

```
import warnings
warnings.simplefilter(action='ignore', category=FutureWarning)
!pip install pandas matplotlib numpy scikit-learn keras tensorflow snfpy


import os
import pandas as pd
import numpy as np
import matplotlib.pyplot as plt
from sklearn.preprocessing import MinMaxScaler
from sklearn.model_selection import train_test_split
from sklearn.metrics import accuracy_score, f1_score, recall_score, precision_score, roc_curve, auc, precision_recall_curve
from keras.models import Sequential, load_model
from keras.layers import Dense, Dropout, BatchNormalization, Input
from keras.callbacks import EarlyStopping, ReduceLROnPlateau, ModelCheckpoint
from tensorflow.keras.regularizers import l1_l2
import snf
from tensorflow.keras.utils import to_categorical
```

```
import numpy as np
import pandas as pd
from sklearn.preprocessing import MinMaxScaler
import snf
base_path = r"C:\Users\sprag\OneDrive\Attachments\Desktop\project"
df_chem_jaccard = pd.read_csv(f"{base_path}\\chem_Jacarrd_sim.csv", index_col=0)
df_atc = pd.read_csv(f"{base_path}\\ATCSimilarityMat.csv", index_col=0)
df_chemical = pd.read_csv(f"{base_path}\\chemicalSimilarityMat.csv", index_col=0)
df_target_jaccard = pd.read_csv(f"{base_path}\\target_Jacarrd_sim.csv", index_col=0)
df_pathway_jaccard =pd.read_csv(f"{base_path}\\pathway_Jacarrd_sim.csv", index_col=0)
df_enzyme_jaccard = pd.read_csv(f"{base_path}\\enzyme_Jacarrd_sim.csv", index_col=0)
df_sideeffect = pd.read_csv(f"{base_path}\\SideEffectSimilarityMat.csv", index_col=0)
df_offsideeffect = pd.read_csv(f"{base_path}\\offsideeffect_Jacarrd_sim.csv", index_col=0)
matrices = [
    df_chem_jaccard.values,
    df_atc.values,
    df_chemical.values,
    df_target_jaccard.values,
    df_pathway_jaccard.values,
    df_enzyme_jaccard.values,
    df_sideeffect.values,
    df_offsideeffect.values
]
datasets = {
    "IntegratedDS1": df_txt,
    "Drug-Drug Matrix": df_drug_drug,
    "DDI Matrix": df_ddi,
    "Chemical Jaccard": df_chem_jaccard,
    "ATC Similarity": df_atc,
```

```
 "Chemical Similarity": df_chemical,
    "Target Jaccard": df_target_jaccard,
    "Pathway Jaccard": df_pathway_jaccard,
    "Enzyme Jaccard": df_enzyme_jaccard,
    "Side Effect Similarity": df_sideeffect,
    "Offside Effect Jaccard": df_offsideeffect,
    "Drug List": df_drug_list
}
  def prepare_data():
    if "IntegratedDS1" not in datasets or "Drug-Drug Matrix" not in datasets:
        raise ValueError("❌ Error: Required datasets not found!")
    drug_fea = MinMaxScaler().fit_transform(datasets["IntegratedDS1"].values)
    interaction = datasets["Drug-Drug Matrix"].values
    fused_similarity = load_similarity_matrices()
    train, label = [], []
              min_size = min(drug_fea.shape[0], fused_similarity.shape[0])
    for i in range(min_size):
        for j in range(min_size):
            if i != j:
              combined_features = list(drug_fea[i]) + list(drug_fea[j]) + [fused_similarity[i, j]]
   train.append(combined_features)
   label.append(int(interaction[i, j]))
  train = np.array(train)
  label = np.array(label)
    unique_labels = np.unique(label)
    print(f"🔷 Unique labels before one-hot encoding: {unique_labels}")
   label = to_categorical(label, num_classes=2)
    print("✅ Train feature vector shape:", train.shape)
    print("✅ Label shape:", label.shape)
    return train, label, drug_fea, fused_similarity
```

```
import numpy as np
def predict_interaction(drug1_name, drug2_name, drug_fea, model, similarity_matrices):
 print("✅ Debug: Inside `predict_interaction()` function")
  if drug1_name not in drug_names or drug2_name not in drug_names:
     return {"Error": "One or both drugs not found!"}
  idx1 = drug_names.index(drug1_name)
  idx2 = drug_names.index(drug2_name)
  drug1_features = drug_fea[idx1]
  drug2_features = drug_fea[idx2]
  similarities = [sim[idx1, idx2] for sim in similarity_matrices]
  print(f"✅ Drug1 Features Shape: {drug1_features.shape}, Drug2 Features Shape:
  {drug2_features.shape}")
   print(f"✅ Similarities Extracted: {len(similarities)}")
 expected_input_size = model.input_shape[1]
    combined_features = np.concatenate([drug1_features.flatten(), drug2_features.flatten(),
    similarities])
     if combined_features.shape[0] > expected_input_size:
     combined_features = combined_features[:expected_input_size]
     else:
     combined_features = np.pad(combined_features, (0, expected_input_size -
    combined_features.shape[0]))
    combined_features = combined_features.reshape(1, -1)
    print(f"🔷 Final Input Shape: {combined_features.shape}")
    prediction = model.predict(combined_features)
     if prediction.shape[-1] == 2:
    predicted_label = np.argmax(prediction)
    probability = float(prediction[0][1])
    else:
     predicted_label = int(prediction[0] > 0.5)
     probability = float(prediction[0])
```

```
        drug1_id = df_drug_list.loc[df_drug_list["Drug Name"] == drug1_name, "DrugBank ID"].values
        drug2_id = df_drug_list.loc[df_drug_list["Drug Name"] == drug2_name, "DrugBank ID"].values
        drug1_id = drug1_id[0] if len(drug1_id) > 0 else "N/A"
        drug2_id = drug2_id[0] if len(drug2_id) > 0 else "N/A"
        drug1_info = drug_info_dict.get(drug1_id, {"Side Effects": "N/A", "Target Sites": "N/A"})
        drug2_info = drug_info_dict.get(drug2_id, {"Side Effects": "N/A", "Target Sites": "N/A"})
        return {
                "Drug 1 Side Effects": drug1_info["Side Effects"],
            "Drug 2 Side Effects": drug2_info["Side Effects"],
            "Drug 1 Target Sites": drug1_info["Target Sites"],
            "Drug 2 Target Sites": drug2_info["Target Sites"]
        }
    drug1, drug2 = get_user_drugs()
    result = predict_interaction(drug1, drug2, drug_fea, model, similarity_matrices)
    print("\n🔷 **Prediction Result** 🔷")
    for key, value in result.items():
        print(f"{key}: {value}")
    print(drug_info_dict)
    !pip install streamlit numpy tensorflow keras pandas
    print(model.input_shape)
    import os
    print(os.path.exists("final_model.keras"))  # Should print True
    from tensorflow.keras.models import load_model
    model = load_model("final_model.keras", compile=False)
    # Check if the model is loaded properly
    print("✅ Model Loaded Successfully!")
    model.summary()  # Print model structure
```

6.5 Testcases and Results

In this study, a deep learning-based model was developed to predict potential drug-drug interactions (DDIs) using a comprehensive fusion of multiple drug similarity matrices. The model was trained on a dataset that integrated diverse features including chemical, ATC, target, enzyme, pathway, side effect, and offside effect similarities. These individual matrices were normalized and fused using Similarity Network Fusion (SNF) to capture the overall relational structure between drugs. The data preparation involved generating combined feature vectors for each unique drug pair, incorporating both the individual drug features and their fused similarity score. The pre-trained model achieved predictions in real-time through a Streamlit-based web interface, allowing users to input drug indices and receive interaction probabilities. The model's output classifies drug pairs as either interacting or non-interacting, with a corresponding probability score to reflect prediction confidence. This tool provides a scalable and efficient approach to DDI prediction, which is critical for minimizing adverse effects in polypharmacy and guiding safe drug co-administration strategies.



Figure 6.1.1 result case 1



Figure 6.1.2 result case 2

```
[57]: drug1, drug2 = get_user_drugs()
      result = predict_interaction(drug1, drug2, drug_fea, model, similarity_matrices)

Enter first drug name:  Ceftriaxone
Enter second drug name:  Acetylsalicylic acid
✅ Debug: Inside `predict_interaction()` function
✅ Drug1 Features Shape: (548,), Drug2 Features Shape: (548,)
✅ Similarities Extracted: 7
🔹 Final Input Shape: (1, 1097)
1/1 ━━━━━━━━━━━━━━━━━━━━ 1s 547ms/step

[58]: print("\n🔹 **Prediction Result** 🔹")
      for key, value in result.items():
          print(f"{key}: {value}")

🔹 **Prediction Result** 🔹
Drug 1: Ceftriaxone
Drug 2: Acetylsalicylic acid
Interaction: No
Probability: 0.3471723198890686
Drug 1 Side Effects: Fever
Drug 2 Side Effects: Nausea
Drug 1 Target Sites: Bacterial cell wall
Drug 2 Target Sites: Cyclooxygenase (COX-1 and COX-2)
```

Figure 7.1.1 test case 1



Figure 7.1.2 test case 1



Figure 7.1.3 test case 2



Figure 7.1.4 test case 3



Figure 7.1.5 test case 4

8. Screen Shots:



Figure 8.1.1 Drug 1 details



Figure 8.1.2 Drug 2 details



Figure 8.1.3 Prediction results of drug 1 and drug 2

CHAPTER-7

7. CONCLUSION

Drug-Drug Interactions (DDIs) represent a critical challenge in modern medicine, influencing the efficacy and safety of pharmacological treatments. As the complexity of medical therapies increases with the rising prevalence of polypharmacy, understanding and predicting these interactions has become more essential than ever. DDIs can lead to altered drug efficacy, adverse reactions, and even life-threatening conditions, making their study a crucial aspect of pharmaceutical research and clinical practice.

Pharmacokinetic and pharmacodynamic interactions form the foundation of DDI mechanisms, affecting drug absorption, metabolism, distribution, and excretion. While some interactions enhance therapeutic effects, others diminish them or lead to toxicity. Conventional methods of DDI detection, such as clinical trials and post-market surveillance, have provided significant insights but remain limited by cost, time constraints, and the inability to capture rare interactions.

The future of DDI research lies in the integration of multi-omics data, electronic health records, and AI-driven predictive models. The development of automated DDI alert systems in clinical settings will further enhance patient safety by reducing medication errors. Additionally, ongoing advancements in personalized medicine will tailor drug prescriptions based on individual patient genetics, minimizing adverse interactions.

In conclusion, understanding DDIs is fundamental to ensuring patient safety and optimizing therapeutic outcomes. The integration of computational methodologies with traditional pharmacological research has opened new avenues for predicting and preventing harmful interactions. By continuously refining these models and expanding the scope of available data, the healthcare industry can significantly reduce the risks associated with drug interactions. As technology advances, the goal remains clear: to develop safer, more effective treatments that maximize therapeutic benefits while minimizing adverse effects, ultimately improving the quality of life for patients worldwide

FUTURE SCOPE

Future Enhancements of the Project

The Drug-Drug Interaction (DDI) prediction model has shown significant potential in identifying potential interactions between pharmaceutical compounds. However, there are several future enhancements that can be incorporated to improve its accuracy, scalability, and clinical applicability.

1. Expanding the Dataset

One of the primary enhancements involves integrating larger and more diverse datasets. By incorporating real-world clinical data from electronic health records (EHRs), adverse drug event (ADE) databases, and publicly available drug interaction repositories, the model can achieve higher predictive accuracy. Additionally, adding genomic and proteomic data will enhance personalized medicine approaches, ensuring drug safety for individuals with different genetic backgrounds.

2. Improved Feature Engineering

Current models rely on chemical, ATC, target, pathway, enzyme, and side-effect similarity measures. Future iterations can incorporate more biological and pharmacological features, such as molecular docking simulations, transcriptomic profiles, and protein-protein interaction networks. Enhancing the representation of drug-drug interactions through graph-based embeddings will further refine the model's ability to detect complex interactions.

3. Advanced Machine Learning Models

Future work can focus on improving the predictive power by using deep learning architectures such as graph neural networks (GNNs) and transformers tailored for biomedical applications. Attention mechanisms can help the model focus on the most relevant features of drug interactions, leading to more precise predictions. Additionally, implementing reinforcement learning can enable adaptive learning from real-time clinical feedback.

4. Real-Time Clinical Integration

For practical applications, the model can be integrated into hospital systems and pharmacy management software. A real-time alert system could notify healthcare professionals about potential drug interactions during prescription processes. Mobile applications or web-based tools can also be developed for public use, enabling patients and pharmacists to check for interactions before administering medications.

5. Enhancing Explainability and Interpretability

To gain clinical trust, the model should provide interpretable explanations for its predictions. Explainable AI (XAI) techniques, such as SHAP (SHapley Additive exPlanations) or LIME (Local Interpretable Model-agnostic Explanations), can be incorporated to justify why a particular drug interaction is predicted. This will assist healthcare professionals in making informed decisions.

6. Incorporating Adverse Event Prediction

Beyond predicting interactions, the model can be expanded to predict the severity and type of adverse events associated with DDIs. This would help categorize interactions as mild, moderate, or severe, guiding clinicians in risk assessment and dosage adjustments.

7. Regulatory Compliance and Validation

To deploy the model in real-world settings, compliance with regulatory standards such as FDA, EMA, and HIPAA must be ensured. Conducting clinical validation studies and collaborating with medical institutions for real-world testing will strengthen the model's credibility and adoption.

CHAPTER-8

8. REFERENCES

1. , S., Shi, J.-Y., & Cao, D.-S. (2024). Comprehensive Review of Drug–Drug Interaction Prediction Based on Machine Learning: Current Status, Challenges, and Opportunities. Journal of Chemical Information and Modeling, 64(1), 96-109.

2. Wahsh, E. A., Abou Warda, A. E., Abdallah, M. S., Elsayed, A., Abdel Daiem, Y. S., & Sadek, E. M. (2024). Assessment of potential drug–drug interaction knowledge, attitude,a cross-sectional multicenter study.

3. Hughes, L. D., & Whiddon, A. R. (2024). Drug–drug interactions and the risk of adverse drug reaction-related hospital admissions in the older population. British Journal of Clinical Pharmacology, 80(4), 782-790.

4. Mohamed, M. R., Mohile, S. G., Juba, K. M., Awad, H., Wells, M., Loh, K. P., Flannery, E. E. (2023). Association of polypharmacy and potential drug–drug interactions with adverse treatment outcomes in older adults with advanced cancer. Cancer, 129(7), 1096-1104.

5. Zhang, X., & Zhu, L. (2023). Network-based prediction of drug–drug interactions using deep learning and multi-source fusion. Briefings in Bioinformatics, 24(2), bbac556.

6. Chen, Y., & Wang, Y. (2023). Predicting drug–drug interactions based on chemical structures: a deep learning approach. Journal of Cheminformatics, 15(1), 12.

7. Li, H., & Zhang, Y. (2022). A comprehensive review of computational methods for drug–drug interaction detection. Briefings in Bioinformatics, 23(1), bbab345.

8. Sun, J., & Zhao, Z. (2022). Drug–drug interaction prediction based on similarity measures and deep learning. Journal of Biomedical Informatics, 128, 104030.

9. Luo, Y., & Zhao, Q. (2021). A network integration approach for drug–drug interaction prediction with heterogeneous information. Journal of Biomedical Informatics, 118, 103777.

10. Zitnik, M., & Leskovec, J. (2021). Predicting multicellular function through multi-layer tissue networks. Bioinformatics, 37(Supplement_1), i190-i198.

11. Santos, V. S., & Pereira, J. V. (2020). Clinical relevance of drug–drug interactions in primary health care: a systematic review. European Journal of Clinical Pharmacology, 76(8), 1089-1100.

12. Vilar, S., & Hripcsak, G. (2020). Drug–drug interaction prediction and extraction: a text-mining review. Journal of the American Medical Informatics Association, 27(2), 192-202

13. Zhang, W., & Zou, H. (2019). Predicting potential drug–drug interactions by integrating chemical, biological, phenotypic, and network data. BMC Bioinformatics, 20(1), 726.

14. Cheng, F., & Zhao, Z. (2019). Machine learning-based prediction of drug–drug interactions by integrating drug phenotypic, therapeutic, chemical, and genomic properties. Journal of the American Medical Informatics Association, 26(9), 806-814.

15. Jiang, Z., & Liu, Q. (2018). A novel approach for the detection of drug–drug interactions based on ensemble learning. Bioinformatics, 34(9), 1648-1655.

16. Ryu, J. Y., & Lee, S. Y. (2018). Deep learning improves prediction of drug–drug and drug–food interactions. Proceedings of the National Academy of Sciences.

17. Kastrin, A., & Ferk, P. (2018). Predicting potential drug–drug interactions on topological and semantic similarity features using statistical learning. Journal of Biomedical Informatics, 84, 104-113.

18. Zhang, P., & Wang, F. (2018). Predicting drug–drug interactions based on biological, chemical, and phenotypic properties. IEEE Transactions on Biomedical Engineering, 65(6), 1257-1265.

19. Liu, Y., & Chen, X. (2018). A network-based approach to predict potential drug–drug interactions by integrating heterogeneous information. Journal of Biomedical Informatics, 85, 68-77.

20. Karim, M. R., & Cochez, M. (2018). Drug–drug interaction prediction based on knowledge graph embeddings and convolutional-LSTM network. Proceedings of the 27th ACM International Conference on Information and Knowledge Management, 1139-1148.